Unilever Q2
This article was originally published in The Rose Sheet
Executive Summary
Dove brand generated double-digit sales growth in North America during the second quarter, driven largely by new products, Unilever reports during Aug. 4 analyst call. Performance helped fuel high single-digit revenue growth in firm's U.S. Personal Care business, company notes. Worldwide Personal Care turnover was up 4.2% to $3.2 bil. (€1=$1.24), representing 5.6% underlying sales growth. Operating profit for the segment improved 4.7% at constant rates to $517.8 mil...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.